Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Terminated

Phase 3 Results

Results

Among these high risk patients with AF(> ¾ of whom were being treated with warfarin at the time of enrollment), clopidogrel/aspirin was inferior to warfarin, resulting in a 1.7% absolute increase (45% relative increase) in the risk of reaching the primary endpoint (5.64% vs. 3.93%, respectively; p=0.0002). The risk of major bleeding was not significantly different between the clopidogrel/aspirin and warfarin groups (2.4% vs 2.2% per year, respectively; p=0.67).